A Multicenter Real-Life Study on the Effect of Flash Glucose Monitoring on Glycemic Control in Patients with Type 1 and Type 2 Diabetes - PubMed (original) (raw)
Multicenter Study
. 2017 Sep;19(9):533-540.
Jothydev Kesavadev 2, Deshpande Neeta 3, Mangesh Tiwaskar 4, Rajendra Pradeepa 1 2, Saravanan Jebarani 1, Suresh Thangamani 1, Nadiminty Ganapathi Sastry 1, Srivastava Brijendra Kumar 1, Muthu Ramu 1, Pokal Prasanna Kumar Gupta 1, Jayaprakash Vignesh 1, Sundramoorthy Chandru 1, Sengottuvel Kayalvizhi 1, Padoor Sethuraman Jagdish 1, Subash Chandra Bose Uthra 1, Munawar Lovelena 1, Sah Jyoti 1, Sengodan Suguna Priya 1, Alagarsamy Kannan 1, Viswanathan Mohan 1, Ranjit Unnikrishnan 1
Affiliations
- PMID: 28930495
Multicenter Study
A Multicenter Real-Life Study on the Effect of Flash Glucose Monitoring on Glycemic Control in Patients with Type 1 and Type 2 Diabetes
Ranjit Mohan Anjana et al. Diabetes Technol Ther. 2017 Sep.
Abstract
Aim: To assess the efficacy of ambulatory glucose profiling (AGP) generated by FreeStyle LibrePro™ flash glucose monitoring (FCGM) on glycemic control in patients with uncontrolled type 1 diabetes (T1D) and type 2 diabetes (T2D).
Methods: Clinical and biochemical data were obtained from 5072 patients with diabetes who had an A1c ≥7% (2536 who had been initiated on FCGM-based AGP between March 2015 and October 2016 [cases] and 2536 age-, gender-, A1c-, site- and time-matched controls who were not initiated on AGP) across seven diabetes clinics in India. Anthropometric and clinical measurements were obtained through standardized techniques. Fasting and postprandial plasma glucose and glycated hemoglobin(A1c) were estimated before and after initiation of AGP.
Results: Overall, there was a significant decrease in A1c both in cases and controls; however, the magnitude of reduction was higher among cases (1% vs.0.7%; P < 0.001).The overall reduction in A1c among cases was higher in T2D (9.2% to 8.3%) compared with T1D (9.6% to 9.4%); however, the absolute difference in A1c reduction between cases and controls was higher among T1D (0.5% vs. 0.2%) patients. The reduction in glycemic parameters was irrespective of age or gender (P for trend <0.001) across all study sites. The greatest reductions in A1c were noted within 6 months of AGP initiation. Multiple logistic regression showed that those who did not use AGP had a 1.42 higher risk (95% CI: 1.24-1.64) of not achieving even 0.1% reduction in A1c compared with those who were initiated on AGP even after adjusting for age, gender, body-mass index, systolic blood pressure, time to follow-up A1c, and medication use.
Conclusions: This study shows that FCGM-based AGP with FreeStyle LibrePro is associated with significant reductions in A1c levels in both T1D and T2D. In addition, improvement in A1c levels was maintained across all age groups and in patients enrolled at different diabetes clinics in India.
Keywords: Ambulatory glucose profile; Continuous glucose monitoring; Diabetes; Glycated hemoglobin; Glycemic control; Indians..
Similar articles
- Impact of a clinical pharmacy program on changes in hemoglobin A1c, diabetes-related hospitalizations, and diabetes-related emergency department visits for patients with diabetes in an underserved population.
Chung N, Rascati K, Lopez D, Jokerst J, Garza A. Chung N, et al. J Manag Care Spec Pharm. 2014 Sep;20(9):914-9. doi: 10.18553/jmcp.2014.20.9.914. J Manag Care Spec Pharm. 2014. PMID: 25166290 Free PMC article. - Real-World Health Outcomes of Insulin Glargine 300 U/mL vs Insulin Glargine 100 U/mL in Adults With Type 1 and Type 2 Diabetes in the Canadian LMC Diabetes Patient Registry: The REALITY Study.
Abitbol A, Brown RE, Jiandani D, Sauriol L, Aronson R. Abitbol A, et al. Can J Diabetes. 2019 Oct;43(7):504-509.e1. doi: 10.1016/j.jcjd.2019.04.012. Epub 2019 May 8. Can J Diabetes. 2019. PMID: 31256905 - Ambulatory glucose profile analysis of the juvenile diabetes research foundation continuous glucose monitoring dataset-Applications to the pediatric diabetes population.
Forlenza GP, Pyle LL, Maahs DM, Dunn TC. Forlenza GP, et al. Pediatr Diabetes. 2017 Nov;18(7):622-628. doi: 10.1111/pedi.12474. Epub 2016 Nov 23. Pediatr Diabetes. 2017. PMID: 27878929 Free PMC article. - Professional flash continuous glucose monitoring as a supplement to A1C in primary care.
Hirsch IB. Hirsch IB. Postgrad Med. 2017 Nov;129(8):781-790. doi: 10.1080/00325481.2017.1383137. Epub 2017 Oct 5. Postgrad Med. 2017. PMID: 28945141 Review. - Type 2 diabetes mellitus: managing hemoglobin A(1c) and beyond.
Fowler GC, Vasudevan DA. Fowler GC, et al. South Med J. 2010 Sep;103(9):911-6. doi: 10.1097/SMJ.0b013e3181eb34b2. South Med J. 2010. PMID: 20689486 Review.
Cited by
- Out-of-pocket expenses and rationing of insulin and diabetes supplies: findings from the 2022 T1International cross-sectional web-based survey.
Souris KJ, Pfiester E, Thieffry A, Chen Y, Braune K, Kapil Bhargava M, Samra R, Gómez P, O'Donnell S. Souris KJ, et al. Front Clin Diabetes Healthc. 2024 Apr 22;5:1293882. doi: 10.3389/fcdhc.2024.1293882. eCollection 2024. Front Clin Diabetes Healthc. 2024. PMID: 38711747 Free PMC article. - Metabolic health tracking using Ultrahuman M1 continuous glucose monitoring platform in non- and pre-diabetic Indians: a multi-armed observational study.
Chaudhry M, Kumar M, Singhal V, Srinivasan B. Chaudhry M, et al. Sci Rep. 2024 Mar 18;14(1):6490. doi: 10.1038/s41598-024-56933-2. Sci Rep. 2024. PMID: 38499685 Free PMC article. - Reliability of Inpatient CGM: Comparison to Standard of Care.
Price C, Ditton G, Russell GB, Aloi J. Price C, et al. J Diabetes Sci Technol. 2023 Mar;17(2):329-335. doi: 10.1177/19322968211062168. Epub 2021 Dec 15. J Diabetes Sci Technol. 2023. PMID: 34911384 Free PMC article. - Factors influencing the effectiveness of using flash glucose monitoring on glycemic control for type 1 diabetes in Saudi Arabia.
Alhodaib HI, Alsulihem S. Alhodaib HI, et al. World J Diabetes. 2021 Nov 15;12(11):1908-1916. doi: 10.4239/wjd.v12.i11.1908. World J Diabetes. 2021. PMID: 34888015 Free PMC article. - Digital health and diabetes: experience from India.
Kesavadev J, Krishnan G, Mohan V. Kesavadev J, et al. Ther Adv Endocrinol Metab. 2021 Nov 17;12:20420188211054676. doi: 10.1177/20420188211054676. eCollection 2021. Ther Adv Endocrinol Metab. 2021. PMID: 34820114 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical